Exploring Fisetin's Potential in Treating Autoimmune Thyroiditis
Results from a Trial of the Senolytic Fisetin in a Single Individual with Autoimmunity 🔗
A trial conducted by Intraclear Biologics explored the effects of the senolytic compound fisetin on a younger individual with autoimmune thyroiditis. Although preliminary, the results provide insight into the potential benefits of fisetin, which may help reduce inflammation linked to senescent cells, a factor in autoimmune diseases. The trial follows the Mayo Clinic's senolytic protocol, using a dosage of fisetin that has shown promise in mouse studies for its safety and efficacy. Notably, while inflammation markers decreased, the autoimmune response did not significantly alter, though the patient's hormone therapy requirements were reduced.
What are senolytic therapies?
Senolytic therapies are treatments designed to selectively eliminate senescent cells, which are damaged cells that can contribute to aging and various diseases.
How does fisetin compare to other senolytic therapies?
Fisetin is considered a safer alternative to other senolytic drugs like dasatinib and quercetin, showing similar effectiveness in preclinical studies while being more readily available and less toxic.
What were the outcomes of the trial on the individual with autoimmune thyroiditis?
The trial showed a reduction in inflammatory markers, but the autoimmune response remained unchanged. The patient's thyroid-stimulating hormone (TSH) levels normalized, allowing for a decrease in hormone therapy dosage.